Tagged with China

Hong Kong Roche has a strong presence in Hong Kong with a local footprint dating back to 1971. Diana Liu, general manager of the Swiss pharma’s Hong Kong & Macau affiliate, outlines its growing local clinical research commitment, one that has seen its clinical trial activities increase 2.5 times and reach an…

China Writing exclusively for PharmaBoardroom, Song Ruilin of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) outlines some of the key improvements and optimisations in the regulatory landscape for pharmaceutical innovation in China. Professor Song also notes the major impact that Chinese innovation is having on global R&D pipelines and…

Hong Kong Managing director of Otsuka Pharmaceutical Hong Kong Koji Ueda explains the Japanese company’s long-standing presence in Hong Kong, which dates back to 1956, the affiliate’s 50-50 split between pharmaceuticals and nutraceuticals and within pharma its principal focus on nephrology and CNS. Moreover, he explains the milestone launch of Otsuka’s first-in-class…

Hong Kong Industry veteran Krish Sundaresan, GM for Hong Kong & Macau at Pfizer for the past two and a half years, shares his experience navigating the shifting dynamics brought on by the COVID-19 pandemic, enhancing omni-channel capabilities, and launching four new products in 2023 alone. Sundaresen also discusses the opportunity to…

Hong Kong Tony Cheng, managing director and general manager for Hong Kong & Macau at Merck Healthcare walks us through the challenges and opportunities arising from Hong Kong’s transformation, Merck’s strong local presence, its collaboration with the Hong Kong Science and Technology Park to support local start-ups, the affiliate’s engagement in the…

China Former director general of the Chinese Center for Disease Control and Prevention (CDC) and current chairman of the Chinese Foundation for Hepatitis Prevention and Control, Professor Yu Wang, weighs in on the country’s strong basic research landscape and the need to reinforce links to investment, the recent regulatory advancements that…

China After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune disease R&D, has a BTK inhibitor for haematological cancers already approved in China and boasts an extensive pipeline. In conversation…

China Since first establishing an affiliate in China back in 2017, Gilead Sciences has been able to introduce 11 innovative medicines to the Chinese market – eight of which have been included in the National Reimbursement Drug List – across HIV prevention & treatment, viral hepatitis, invasive fungal disease, and cancer.…

China Jimmy Wei founded Chime Biologics over 12 years ago with the vision of establishing a global biologics company in China, focusing on biosimilar development and CDMO services. The company’s growth since then has been influenced by the success of other biologics companies like WuXi Biologics and Samsung Biologics, regulatory changes…

China Boan Biotech CEO Jiang Hua outlines the Luye Pharma-acquired company’s approach, securing stable revenues through its biosimilars while pursuing novel platforms and innovative drug development. She provides insights into the biotech’s six biosimilar products, as well as its main technology platforms – including the foundational Human Antibody Transgenic Mouse platform…

China BeiGene may not be a profitable business quite yet, but the Chinese biotech has two top oncology products and saw its sales soar to USD 2.2 billion in 2023. Having set its sights on markets outside of China, with its BTK inhibitor Brukinsa already approved across multiple geographies, the company…

China Cytiva is a global leader in bioprocessing technologies and services that support the manufacturing and research of biopharmaceuticals. China is a key market in the company’s growth story, where – as President of Cytiva in China Allen Li notes – it has shifted from simply offering superior products to engaging…